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Previous animal studies have demonstrated that 
dobutamine (DBT), a mildly (3-4 fold) selective B, 
agonist, has an intrinsic activity (relative to 
(ISO)) of .8 to 1.0. Because of species 
variation in adrenergic receptor-effecter mechanisms 
we assessed the activity of DBT in human q yocardial 13 
adrenergic receptor systems. We examined the contractile 
response of DBT and IS0 in isolated right ventricular 
trabeculae prepared from end stage failing hearts (n-16) 
removed from transplant recipients and nonfailing heares 
(n=6) taken from organ donors. Additionally, I3 
adrenergic receptor density, 6,/B, receptor subtype 
distributions and adenylate cyclase (AC) activity were 
measured in crude myocardial membranes: (values + SEM) 
NET TZNSION A.C. (pmol RECEPTCX; 
(m&9 cAMP/min/mg) ( fmWmg) 
IS0 DBT IS0 DBT f3 Total B, R, 
NF 2262 # 1158 43.1 115.4 83.3 64.8 18.8 
.583 
F *i2ii 
2385 f1.7 25.2 k8.1 k6.3 k1.8 
*425 25.6 3.5 *56.9 *32.7 23.7 
2173 273 k4.4 k2.5 21.8 
*,p c.05 vs NF; #,p <.OS vs IS0 
The tension data yield an intrinsic activity for DBT of 
.51 in nonfailing and .44 in failing q yocardium. 
CONCLUSION; DBT has relatively less efficacy in human 
compared to animal myocardium, perhaps because of a 
lower coupling ratio and no receptor reserve in the 
human heart. The partial agonist properties of DBT must 
be kept in mind in clinical situations that call for 
maximal inotropic stimulation. 
Pm% 44+l2* 28214 26212 
HF Power 21042 I2168 lsto+ 1402 11462 1070 
* differs horn placebo at p <O.OOI 
Conchlsioa!x 
On placebo, al subjects than in patients after 
myocardial infarction. $3 caused a large increase in PSA, an effect which 
stabilizes the heart electrically. CCB had no effect on PSA. The differences 
between ,9B anil CCB eflects on PSA may explain, in part, t&e improved survival 
after MI associated with BB. but not with CCB, treatment. 
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GM2191 B Is a novel thromboxane A2 receptor antagonist with potent 
antlaggregatlonal and anti-vasoconstrictive properties. To study whether this 
compound is useful in restenosis prevention after coronary angioplasty (PTCA), 
we have conducted a randomised. double blind, placebo controiied trial. 
Patients (pts) were randomized to receive either GR321918,6O mg intravenous 
before PTCA and 40 mg orally for 6 months, or 250 mg IntQvsnous aspirin 
before PTCA and placebo for 6 months. Coronary angiograms before PTCA, 
after PTCA and at 6 months follow up were quantitatively analyzed, using an 
automated edge detection technique. 
PTCA was attempted in 697 pts. Failure of the procedure occurred in 
17 pts (6.7%). Follow up angiography was available in 88.5% (575 pts) of 
successfully treated pts. In 53 pts drug compliance was less then 80% or trial 
medication was discontinued for more then 3 consecutive days. Quantitative 
data from these pts were excluded from analysis in accordance with the 
protocol. Baseline clinical and angiognphic parameters did not differ between 
the two treatment groups. Multiple matched view analysis was performed on 
306 segments (231 pts) In the placebo group (plgr) and on 308 segments (261 
pts) in the acthe treatment group (trgr). 
The ml!an coronary diameter (cordia) after PTCA was 1.77 + 0.35 mm 
in the plgr and 1.79 + 0.33 mm in the trgr (NS). Cordia at follow up angiography 
was 1.46 f 0.53 mm In the plfgr and 1.49 2 0.58 mm in the trgr. The mean 
difference in coronary diameter between post PTCA and follow up angiogram. 
as a measure for intimal hyperplasia, was -0.31 2 0.53 mm in the plgr and -0.30 
+ 0.54 mm in the trgr (NS). 
Clinical events during follow up, analyed on intention to treat basis, are 
ranked according to the highest category on a scale ranging from death (plgr 
3, trgr 2), nonfatal infarction (plgr 20, trgr 15), bypass grafting (plgr 16. trgr 23), 
re-PTCA (plgr 52, trgr 47). NYHA class III/IV (plgr 33. trgr 35), NYHA class II 
(plgr 70, trgr 76) to no event (plgr 132, trgr 133). No significant difference in 
ranking wa: detected between the two treatment groups. 
Long term thromboxane A2 receptor blockade with GR32191B. used 
as a single pharmacologic regimen, does not prevent intimal hyperplasia and 
does not favourably influence the longterm clinical course following PTCA. 
Continuous intravenous iafus ion of adenosine produces 
coronary hyperemia equivalent to intracoronary papaver- 
ine (PAP) and is useful for extended coronary hyperemic 
stimulation wiihout adverse electrophysiologic effects. 
To assess whether low dose single IV bolus adenosine 
produces comparable coronary hyperemia, we measured 
coronary blood flow velocity (2OMhz Doppler catheter), 
heart rate and mean arterial pressure in 17 pts (7 with 
and 10 without coronary artery disease) at rest and 
during maximal hyperemia during 1Omg intracoronary PAP, 
3 minute IV infusion lOOmcg/kg adenosine (AD1001 and 
during IV bolus 2.5mg adenosine (AD2.5). Coronary re- 
serve (CVR) was calculated as peak-hyperemic/basal mean 
velocity (Hv). Results: (mean+SD) (“~(0.05 vs PAP) 
AD100 PAP AD2.5 
CVR (units) 2.27eO.73 ?fziTix 2.17+0.91” 
NV (cm/set) 60:30 68;30 58:23* 
Correlation between methods (AD100 vs PAP, AD100 VB 
AD2.5 and PAP vs AD2.5) for CVR were v0.830, 0.725 and 
0.914 and for Ml, ra0.872, 0.765 and 0.844, respective- 
ly (all p<O.OOl). Time to peak hyperemia from femoral 
vein injection was 17+6 seconds with return to baseline 
by 20+5 seconds. An-additional IV bolue 5% adenosine 
failed to augment the mean velocity achieved with 2.5mg 
in 719 pte. These data indicate that low dose IV bolue 
adenosine produces transient coronary hyperemia equiva- 
lent to prolonged IV infusion, but lower than intracoro- 
nary P.iP, and is suitable for repetitive determinations 
of CVR in pts. 
